Trastuzumab Deruxtecan in Solid Tumours Harbouring HER2 Mutations
1. The objective response rate for trastuzumab deruxtecan was 29.4%. 2. Treatment-emergent adverse event grade 3 or higher was seen ...
Tag: trastuzumab deruxtecan
Trastuzumab deruxtecan superior to physician’s choice treatment in patients with metastatic HER2-positive breast cancer
1. Progression-free survival was greater in the trastuzumab group compared to standard care (17.8 months vs. 6.9 months). 2. Drug-related ...
Trastuzumab deruxtecan is a treatment option for pre-treated HER2-low metastatic breast cancer
1. Median overall survival is longer for HER2-low breast cancer patients receiving trastuzumab deruxtecan compared with other chemotherapy treatment options. ...
Trastuzumab deruxtecan associated with lower risk of metastatic breast cancer progression
1. Compared to trastuzumab emtansine, trastuzumab deruxtecan is associated with a lower risk of disease progression or death in patients ...
Trastuzumab deruxtecan superior to trastuzumab emtansine in patients with metastatic HER2 breast cancer
1. Longer progression-free survival was found in patients taking trastuzumab deruxtecan compared to trastuzumab emtansine 2. Adverse events were more ...
Trastuzumab deruxtecan showed therapeutic efficacy in HER2-mutant non-small cell lung cancer
1. Patients with refractory HER2-mutant non-small cell lung cancer (NSCLC) show clinical response to trastuzumab deruxtecan. 2. Safety profiles were ...